Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid/orbital edema, or lid/orbital erythema recommended for treatment with teprotumumab infusion (Tepezza®). Patients recommended for treatment will be evaluated by an oculoplastic surgeon (Dr. Eva Chou) and endocrinologist (Dr. Thanh Hoang).

Who May Be Eligible (Plain English)

Who May Qualify: - only DOD beneficiaries - adult patients 18 years of age or older - adult patients with proptosis, ocular/orbital pain, diplopia, lid/orbital edema, or lid/orbital erythema associated with autoimmune thyroid disease Who Should NOT Join This Trial: - Patients with evidence of compressive optic neuropathy necessitating urgent orbital decompression or external beam radiation - patients with a history of uncontrolled diabetes mellitus - patients with a history/diagnosis of uncontrolled inflammatory bowel disease - patients under age 18 years - patients who are pregnant or trying to become pregnant. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * only DOD beneficiaries * adult patients 18 years of age or older * adult patients with proptosis, ocular/orbital pain, diplopia, lid/orbital edema, or lid/orbital erythema associated with autoimmune thyroid disease Exclusion Criteria: * Patients with evidence of compressive optic neuropathy necessitating urgent orbital decompression or external beam radiation * patients with a history of uncontrolled diabetes mellitus * patients with a history/diagnosis of uncontrolled inflammatory bowel disease * patients under age 18 years * patients who are pregnant or trying to become pregnant.

Treatments Being Tested

DRUG

Teprotumumab Injection [Tepezza]

IGF1 monoclonal antibody

Locations (1)

Walter Reed National Military Medical Center
Bethesda, Maryland, United States